{[(2R,3R,4S,5S)-2-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy}({[(2S,3R,4R,5R)-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid

• ChemBase编号: 3296
• 分子式: C19H25N8O12P
• 平均质量: 588.421961
• 单一同位素质量: 588.13295491
• SMILES: Nc1nc2c(ncn2[C@@H]2O[C@@H](CO[P@](=O)(O)O[C@@H]3[C@@H](O)[C@H](CO)O[C@H]3n3ccc(N)nc3=O)[C@H](O)[C@H]2O)c(=O)[nH]1
• Canonical SMILES: OC[C@@H]1O[C@H]([C@@H]([C@H]1O)O[P@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1O)O)n1cnc2c1nc(N)[nH]c2=O)O)n1ccc(nc1=O)N
• InChI: InChI=1S/C19H25N8O12P/c20-8-1-2-26(19(33)23-8)17-13(11(30)6(3-28)37-17)39-40(34,35)36-4-7-10(29)12(31)16(38-7)27-5-22-9-14(27)24-18(21)25-15(9)32/h1-2,5-7,10-13,16-17,28-31H,3-4H2,(H,34,35)(H2,20,23,33)(H3,21,24,25,32)/t6-,7-,10-,11-,12+,13+,16+,17+/m0/s1
• InChIKey: QZDUXDLOEVJGDG-BWDUBGIRSA-N

名称和登记号

名称

• IUPAC标准名: {[(2R,3R,4S,5S)-2-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy}({[(2S,3R,4R,5R)-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid
• IUPAC传统名: [(2R,3R,4S,5S)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl]oxy[(2S,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxyphosphinic acid
• 别名: Cytidyl-2'-5'-Phospho-Guanosine

登记号

• PubChem SID: 46505014; 160966738
• PubChem CID: 46936739

理论计算性质

JChem

• Acid pKa: 2.029142
• 质子受体: 15
• 质子供体: 8
• LogD (pH = 5.5): -7.0621786
• LogD (pH = 7.4): -7.107185
• Log P: -4.938064
• 摩尔折射率: 126.2598 cm^3
• 极化性: 49.21058 Å^3
• 极化表面积: 299.13 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -1.93
• LOG S: -2.19
• 溶解度: 3.79e+00 g/l

详细说明

DrugBank - DB03638

Drug information: experimental